title: Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.
abstract: OCT2 is the entry step for organic cation (OC) secretion by renal proximal tubules. Although many drugs inhibit OCT2 activity, neither the mechanistic basis of their inhibition nor their transport status is generally known. Using representatives of several structural classes of OCT2-inhibitory ligands described recently (Kido Y, Matsson P, Giacomini KM. J Med Chem 54: 4548-4558, 2011), we determined the kinetic basis of their inhibition of 1-methyl-4-phenylpyridinium (MPP) transport into Chinese hamster ovary cells that stably expressed hOCT2. The "cluster II" inhibitors (which contain known OCT2 substrates) metformin and cimetidine interacted competitively with MPP. However, other cluster II compounds, including tetraethylammonium (TEA), diphenidol and phenyltoloxamine, were mixed-type inhibitors of MPP transport (i.e., decreasing J(max) and increasing K(t)). A cluster III (neutral steroid) representative, adrenosterone, and a cluster I (large, flexible cation) representative, carvedilol, displayed noncompetitive inhibitory profiles. Competitive counterflow (CCF) was used to determine whether the inhibitory ligands served as substrates of hOCT2. Carvedilol (cluster I) and adrenosterone (cluster III) did not support CCF, consistent with the prediction that members of these structural classes are likely to be nontransported inhibitors of OCT2. The cluster II representatives MPP, metformin, cimetidine, and TEA all supported CCF, consistent with independent assessments of their OCT2-mediated transport. However, the other cluster II representatives, diphenidol and phenyltoloxamine, failed to support CCF, suggesting that neither compound is transported by OCT2. An independent assessment of diphenidol transport (using liquid chromatography with tandem mass spectroscopy) confirmed this observation. The results underscore the caution required for development of predictive models of ligand interaction with multidrug transporters.
authors.affiliation: Univ. of Arizona College of Medicine, Dept. of Physiology, Tucson, AZ 85724, USA.
authors.forename: Jaclyn N
authors.initials: JN
authors.lastname: Harper
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Wright
mesh_terms: D015655:1-Methyl-4-phenylpyridinium / Q000378:metabolism*; D000736:Androstenes / Q000494:pharmacology; D000818:Animals; D001559:Benzhydryl Compounds / Q000378:metabolism; D016466:CHO Cells; D002227:Carbazoles / Q000494:pharmacology; D000077261:Carvedilol; D002927:Cimetidine / Q000378:metabolism; D006224:Cricetinae; D003412:Cricetulus; D006801:Humans; D020128:Inhibitory Concentration 50; D007700:Kinetics; D008024:Ligands; D008687:Metformin / Q000378:metabolism; D027701:Organic Cation Transport Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000075102:Organic Cation Transporter 2; D010880:Piperidines / Q000378:metabolism; D011412:Propanolamines / Q000494:pharmacology; D019789:Tetraethylammonium / Q000378:metabolism
chemical_list: D000736:Androstenes; D001559:Benzhydryl Compounds; D002227:Carbazoles; D008024:Ligands; D027701:Organic Cation Transport Proteins; D000075102:Organic Cation Transporter 2; D010880:Piperidines; D011412:Propanolamines; C491013:SLC22A2 protein, human; D000077261:Carvedilol; D019789:Tetraethylammonium; D002927:Cimetidine; D008687:Metformin; C011657:adrenosterone; C008865:phenyltoloxamine; C004858:diphenidol; D015655:1-Methyl-4-phenylpyridinium